navigation bar


“Arresto: Blocking fibroblasts”
Emerging Company Profile featured in the June 28, 2010 issue of BioCentury. 
PDF IconPDF Download

Arresto BioSciences™ recently published a novel drug strategy that combines the advantages of allosteric modulators of enzymatic function with the specificity, selectivity, and pharmacologic properties of antibodies. Arresto BioSciences™ is using this approach to develop novel therapeutics for treating conditions such as oncology, fibrosis and inflammation.

Modulation of lysyl oxidase-like 2 enzymatic activity by an allosteric antibody inhibitor
Hector M. Rodriguez, Maria Vaysberg, Amanda Mikels, Scott McCauley, Arleene C. Velayo, Carlos Garcia and Victoria Smith
The Journal of Biological Chemistry, in press. Published on May 3, 2010.
http://www.jbc.org/cgi/doi/10.1074/jbc.M109.094136





 

footer
About Arresto | R&D | Investors | News | Careers | Contact Us